IP Library Granted Patent US 11,318,204
Granted Patent B2
US 11,318,204 · App. 15/373,174 · Granted May 3, 2022

Composition for intravascular delivery of therapeutic composition

Inventor: Ralph A. Chappa (Ham Lake, MN)
Assignee: Surmodics, Inc.
A61K47/22A61K9/0019A61K31/337A61K31/436A61L29/16A61M25/0026A61M25/0045A61M25/1011A61L2300/416A61M25/0009A61M25/1029A61M2025/1004A61M2025/105A61M2025/1013A61M2025/1088
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,318,204
App. No.
15/373,174
Granted
May 3, 2022
Kind
B2
Abstract

The present invention relates to a pharmaceutical composition for intravascular delivery of a therapeutic agent, such as paclitaxel, rapamycin, or an analog thereof. The composition includes the therapeutic agent and a biocompatible solvent, such as glycofurol. The composition can aid tissue penetration by the therapeutic agent. A catheter assembly that protects the pharmaceutical composition from the surroundings can be used for its intravascular delivery.

Claims (11)

1. An intra-arterial catheter comprising a reservoir consisting of a pharmaceutical composition solution of paclitaxel in an amount in the range of 5 to 40 wt-% and glycofurol in an amount in the range of 60 to 95 wt-% wherein paclitaxel and glycofurol total 100% of components of the pharmaceutical composition solution, wherein the reservoir delivers the pharmaceutical composition solution to an exposed interior surface of an artery using a balloon in order for the paclitaxel to appear as a solid on the exterior of the artery after delivery to the interior surface of the artery to treat arterial disease, said arterial disease characterized by blocked intraluminal channel(s),

wherein (a) the balloon of the catheter comprises an inner expandable and collapsible structure and an outer expandable and collapsible structure, the inner and outer expandable and collapsible structures configured to expand between a contracted state and a dilated state, the inner and outer expandable and collapsible structures defining a cavity therebetween which is the reservoir for the composition, wherein the outer expandable and collapsible structure comprises openings in the dilated state that allow the composition solution to move from the reservoir to the interior surface of an artery, or (b) the catheter comprises a catheter shaft, and the reservoir is a lumen in the catheter shaft and in fluid communication with the balloon, and the composition solution is released from the balloon upon expansion of the balloon.

2. The catheter of claim 1 , wherein the pharmaceutical composition solution has paclitaxel in an amount in the range of about 5 to about 10 wt-% and glycofurol in an amount in the range of about 90 to about 95 wt-%.

3. The catheter of claim 1 , wherein the pharmaceutical composition solution has paclitaxel in an amount in the range of about 10 to about 30 wt-% and glycofurol in an amount in the range of about 70 to about 90 wt-%.

4. The catheter of claim 1 , wherein the pharmaceutical composition solution has paclitaxel in an amount in the range of about 5 to about 15 wt-% and glycofurol in an amount in the range of about 85 to about 95 wt-%.

5. The catheter of claim 1 , wherein the pharmaceutical composition solution has paclitaxel in an amount in the range of about 10 to about 20 wt-% and glycofurol in an amount in the range of about 85 to about 95 wt-%.

6. The catheter of claim 1 , wherein the pharmaceutical composition solution has paclitaxel in an amount in the range of about 20 to about 30 wt-% and glycofurol in an amount in the range of about 70 to about 80 wt-%.

7. The catheter of claim 1 comprising a polymer coating on the outer surface of the outer expandable and collapsible structure.

8. The catheter of claim 1 , wherein the paclitaxel functions as an antiproliferative agent for the treatment of diseased arterial tissue that causes the blocked intraluminal channel(s).

9. The catheter of claim 1 , wherein the interior surface of the artery having said arterial disease is also treated by expansion of the balloon of the balloon catheter.

10. The catheter of claim 1 , wherein the openings in the outer expandable and collapsible structure are configured to be closed when the structure is in the contracted state.

Assignments (4)
SECURITY INTEREST Recorded Jan 21, 2026
From: SURMODICS COATINGS, LLC
To: BANK OF MONTREAL, AS COLLATERAL AGENT
Reel/Frame 074461/0162 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2025
From: SURMODICS, INC.
To: SURMODICS COATINGS, LLC
Reel/Frame 073928/0178 →
RELEASE OF SECURITY INTEREST Recorded Nov 24, 2025
From: MIDCAP FUNDING IV TRUST
To: SURMODICS, INC.; SURMODICS SHARED SERVICES, LLC; SURMODICS HOLDINGS, LLC; SURMODICS COATINGS, LLC; SURMODICS MD, LLC; SURMODICS COATINGS MFG, LLC; SURMODICS IVD, INC.; SURMODICS MD OPERATIONS, LLC; NORMEDIX, INC.
Reel/Frame 073690/0186 →
SECURITY INTEREST Recorded Aug 23, 2024
From: SURMODICS, INC.; SURMODICS SHARED SERVICES, LLC; SURMODICS HOLDINGS, LLC; SURMODICS COATINGS, LLC; SURMODICS MD, LLC; SURMODICS COATINGS MFG, LLC; SURMODICS IVD, INC.; SURMODICS MD OPERATIONS, LLC; NORMEDIX, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 068762/0423 →
Continuity (4)
Continuation 14613532 · Feb 4, 2015
Continuation 13339908 · Dec 29, 2011
Provisional Application 61428397 · Dec 30, 2010
Related Publication 20170095559A1 · Apr 6, 2017